Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma The Non-Hodgkin's lymphoma classification project. Blood. 1997;89(11):3909–3918.
   PubMed Web of Science ®Google Scholar
• Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–87.
   PubMedGoogle Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des lymphomes de l'Adulte (GELA). Blood. 1998;92(1):76–82.
   PubMed Web of Science ®Google Scholar
• Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40(5):443–450.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Savage KJ, Harris NL, et al.; for the International Peripheral T-cell Lymphoma Project. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood. 2011;117(12):3402–3408.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D, et al.; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093–3099.
   PubMed Web of Science ®Google Scholar
• Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106–113.
   PubMed Web of Science ®Google Scholar
• Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9):1533–1538.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Conde E, Gutierrez A, et al.; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea, Spanish Lymphoma/Autologous Bone Marrow Transplant Study Group. The adjusted international prognostic index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica. 2007;92(8):1067–1074.
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Caballero MD, Perez-Manga G, et al. Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant. 2008;42(12):773–781.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood. 1994;84(4):1050–1055.
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22(11):2172–2176.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Awan FT, Elder P, et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant. 2008;14(4):480–483.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the american society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2017;23(11):1826–1838.
   PubMed Web of Science ®Google Scholar
• Modi D, Surapaneni M, Kim S, et al. Allogeneic stem cell transplant provides durable response in peripheral T-cell lymphoma. Leuk Res. 2019;83:106171.
   PubMed Web of Science ®Google Scholar
• Gu Z, Wang L, Wang Q, et al. Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas. Ann Hematol. 2019;98(5):1237–1247.
   PubMed Web of Science ®Google Scholar
• Wulf G, Hasenkamp J, Jung W, et al. Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transplant. 2019;54(6):877–884.
   PubMed Web of Science ®Google Scholar
• Huang H, Jiang Y, Wang Q, et al. Outcome of allogeneic and autologous hematopoietic cell transplantation for High-Risk peripheral T cell lymphomas: a retrospective analysis from a chinese center. Biol Blood Marrow Transplant. 2017;23(8):1393–1397.
   PubMed Web of Science ®Google Scholar
• Bo J, Zhao Y, Zhang S, et al. Long-term outcomes of peripheral blood stem cell transplantation for 38 patients with peripheral T-cell lymphoma. J Cancer Res Ther. 2016;12(3):1189–1197.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Aoki K, Kondo T, et al. Outcome of allogeneic hematopoietic stem cell transplantation in cases of mature T/NK-cell neoplasms: a single-center retrospective analysis. Ann Hematol. 2017;96(2):323–326.
   PubMed Web of Science ®Google Scholar
• Loirat M, Chevallier P, Leux C, et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol. 2015;26(2):386–392.
   PubMed Web of Science ®Google Scholar
• Smith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31(25):3100–3109.
   PubMed Web of Science ®Google Scholar
• Czajczynska A, Gunther A, Repp R, et al. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2013;19(11):1632–1637.
   PubMed Web of Science ®Google Scholar
• Robles M, Vigouroux S, Tabrizi R, et al. Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response. Bone Marrow Transplant. 2013;48(11):1484–1485.
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Kasamon YL, Gocke CD, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013;19(4):602–606.
   PubMed Web of Science ®Google Scholar
• Kim SW, Yoon SS, Suzuki R, Matsuno Y, et al. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with Central review of pathology. Leukemia. 2013;27(6):1394–1397.
   PubMed Web of Science ®Google Scholar
• Goldberg JD, Chou JF, Horwitz S, et al. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2012;53(6):1124–1129.
   PubMed Web of Science ®Google Scholar
• Dodero A, Spina F, Narni F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26(3):520–526.
   PubMed Web of Science ®Google Scholar
• Zain J, Palmer JM, Delioukina M, et al. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma. 2011;52(8):1463–1473.
   PubMed Web of Science ®Google Scholar
• Delioukina M, Zain J, Palmer JM, et al. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant. 2012;47(1):65–72.
   PubMed Web of Science ®Google Scholar
• Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/sezary syndrome. Ann Oncol. 2011;22(7):1608–1613.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Milpied N, Buzyn A, et al.; Société Française de Greffe de Moëlle et de Thérapie Cellulaire. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008;26(14):2264–2271.
   PubMed Web of Science ®Google Scholar
• Du J, Yu D, Han X, et al. Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-Cell lymphoma: a systematic review and Meta-analysis. JAMA Netw Open. 2021;4(5):e219807.
   PubMed Web of Science ®Google Scholar
• Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–63.
   PubMedGoogle Scholar
• Shustov AR, Gooley TA, Sandmaier BM, et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol. 2010;150(2):170–178.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, El-Jurdi N, Ayala E, et al. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? Bone Marrow Transplant. 2017;52(11):1487–1494.
   PubMed Web of Science ®Google Scholar
• Shiratori S, Fujimoto K, Nishimura M, et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and sezary syndrome. Hematol Oncol. 2016;34(1):9–16.
   PubMed Web of Science ®Google Scholar
• Gabriel IH, Olavarria E, Jones RR, et al. Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides. Bone Marrow Transplant. 2007;40(4):401–403.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Ahmed S, Ahn KW, et al. Association of Reduced-Intensity conditioning regimens with overall survival among patients with Non-Hodgkin lymphoma undergoing allogeneic transplant. JAMA Oncol. 2020;6(7):1011–1018.
   PubMed Web of Science ®Google Scholar
• Kurosawa S, Yakushijin K, Yamaguchi T, et al. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan transplant outcome registry. Bone Marrow Transplant. 2013;48(4):529–536.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kurosawa S, Tajima K, et al. Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51(4):553–559.
   PubMed Web of Science ®Google Scholar
• Mamez AC, Dupont A, Blaise D, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the societe francophone de greffe de moelle et de therapie cellulaire (SFGM-TC). J Hematol Oncol. 2020;13(1):56.
   PubMed Web of Science ®Google Scholar
• Freytes CO, Loberiza FR, Rizzo JD, Lymphoma Working Committee of the International Bone Marrow Transplant Registry, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the international bone marrow transplant registry. Blood. 2004;104(12):3797–3803.
   PubMed Web of Science ®Google Scholar